New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2013
12:27 EDTAMGNEarnings Preview: Amgen shares up sharply in July ahead of Q2 results
Amgen (AMGN) is scheduled to report Q2 earnings after the market close on Tuesday, July 30, with a conference call scheduled for 5:00 pm ET. Amgen is an American-based multinational biopharmaceutical company headquartered in Thousand Oaks, California. EXPECTATIONS: Analysts are looking for EPS of $1.74 on revenue of $4.49B, according to First Call. The consensus range for EPS is $1.66-$1.83 on revenue of $4.35B-$4.57B. LAST QUARTER: Amgen reported Q1 EPS of $1.96 against estimates of $1.84 on revenue of $4.2B, against estimates of $4.37B. STREET RESEARCH: On May 1, Amgen was upgraded to Conviction Buy from Neutral at Goldman. Goldman upgraded Amgen based on valuation and its late-stage pipeline which is highly innovative and has the potential to replace key biologic franchises that are coming off patent. Goldman raised its price target to $130 from $100 on Amgen shares. PRICE ACTION: Amgen shares have rallied approximately 15% since early July and are up 0.9% on the day to $110.35
News For AMGN From The Last 14 Days
Check below for free stories on AMGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
08:21 EDTAMGNAmgen submitts MAA to EMA for evolocumab
Subscribe for More Information
08:20 EDTAMGNAmgen submits application to EMA for talimogene laherparepvec
Subscribe for More Information
08:01 EDTAMGNAmgen price target raised to $153 from $140 at Leerink
Subscribe for More Information
August 31, 2014
12:50 EDTAMGNEuropean Society of Cardiology to hold a conference
Subscribe for More Information
August 28, 2014
09:18 EDTAMGNAmgen anounces Evolocumab YUKAWA-2 study meets co-primary endpoints
Subscribe for More Information
09:04 EDTAMGNAmgen submits evolocumab BLA to FDA
Subscribe for More Information
August 27, 2014
09:20 EDTAMGNFDA grants Amgen priority review designation for ivabradine
Amgen announced the U.S. Food and Drug Administration has granted priority review designation for ivabradine for the treatment of chronic heart failure. Ivabradine is an oral drug that inhibits the If current in the sinoatrial node, the body's cardiac pacemaker. The New Drug Application is based on global clinical trial data from the Phase 3 SHIFT, or Systolic Heart failure treatment with the If inhibitor ivabradine Trial), study. The SHIFT study compared ivabradine to placebo on top of standard-of-care therapies, including beta-blockers, in more than 6,500 patients in sinus rhythm with reduced left ventricular function and heart rate greater than 70 beats per minute.
August 26, 2014
11:21 EDTAMGNAmgen added to short term buy list at Deutsche Bank
Subscribe for More Information
August 25, 2014
16:17 EDTAMGNWestern Digital CFO Leyden to retire, Olivier Leonetti to succeed
Western Digital (WDC) announced that CFO Tim Leyden is retiring. He is being succeeded by Olivier Leonetti, who has served as vice president, finance at Amgen (AMGN) from 2011. Leyden will remain with the company through January 2015 in a transition role and advisory capacity to president and chief executive officer Steve Milligan and to Leonetti for an interim period to ensure a smooth transition. The changes are effective as of September 8.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use